Related Experiment Videos
[Infarct-typical changes in the electrocardiogram following chemotherapy with vinblastine]
1Medizinische Klinik II, Städtische Kliniken Kassel.
Deutsche Medizinische Wochenschrift (1946)
|April 14, 1989
Summary
Vinblastine chemotherapy may cause myocardial damage, presenting as chest pain and ECG changes. This cardiac event occurred in a patient undergoing treatment for testicular cancer.
Area of Science:
- Cardiology
- Oncology
- Pharmacology
Background:
- A 47-year-old man with a history of orchiectomy for embryonic carcinoma of the testes was undergoing chemotherapy.
- The patient was receiving a combination regimen including vinblastine, bleomycin, and cisplatin.
Observation:
- The patient experienced left-chest pain and electrocardiogram (ECG) changes indicative of myocardial infarction during the second chemotherapy cycle.
- Cardiac enzyme elevation was minimal, and coronary angiography revealed no obstructive coronary artery disease.
- A ventriculogram demonstrated apical akinesia, suggesting impaired left ventricular function.
Findings:
- Recurrent chest pain and ECG abnormalities occurred during the third cycle, even when bleomycin was omitted.
- This clinical course strongly implicates vinblastine as the causative agent for the observed myocardial damage.
- The precise mechanism (pathogenesis) of vinblastine-induced cardiotoxicity remains unclear.
Implications:
- Vinblastine, a vinca alkaloid chemotherapy agent, may be associated with significant cardiac adverse events.
- Clinicians should consider potential cardiotoxicity in patients receiving vinblastine, particularly those with pre-existing cardiovascular risk factors or undergoing combination chemotherapy.
- Further research is warranted to elucidate the pathogenesis of vinblastine-induced myocardial damage and to develop strategies for prevention and management.